At London Predictive Toxicology Summit Asymmetrex Presents New...

Although pharmaceutical companies recognize that promising new drugs that are toxic to adult stem cells are likely to fail, the industry has been unable to do much about this problem, which is estimated to cost billions of dollars each year due to futile drug studies. On February 18 at the 7th Annual Predictive Toxicology Summit in London, Dr. James Sherley, Director of Asymmetrex LLC, told an international audience of pharmaceutical executives and toxicologists that new technologies from his company are now available to address this adult stem cell toxicity detection problem.

http://ift.tt/1Lg7eXf